Laboratoriumonderzoek speelt bij 70% van de diagnoses een sleutelrol
Wij nemen uw bloed serieus!
|Onderzoekslijnen||Alle projecten||Alle publicaties en voordrachten||Instituten|
|Project 58||Evaluation of Circulating Epithelial Cells in Patients with Newly Diagnosed Breast or Colorectal Cancers|
|Onderzoekslijn||Apoptosis and tumorgenesis|
|Omschrijving||Over the past several years immunomagnetic separation technology, with its greater sensitivity and specificity, has been used as a means to improve detection of circulating cancer cells. In this technique, the specimen is incubated with magnetic beads coated with antibodies directed against epithelial cells 14. The epithelial cells are then isolated using a powerful magnet. The non-magnetic supernatant fraction can be used for downstream RT-PCR, while the magnetic fraction can be subsequently enumerated and characterized using fluorescent microscopy and/or flow cytometry analyses. By combining proprietary immunomagnetic enrichment technology, immunofluorescent labeling technology, and an appropriate analytical platform, the University of Twente developed in cooperation with Immunicon a test with the requisite sensitivity and specificity to detect these rare cells in a sample of whole blood and to investigate their role in the clinical course of disease in malignant tumors of epithelial origin.
The clinical significance of circulating tumor cells (CTCs) remains controversial. Correct identification and quantification is the primary step in addressing this issue. Thereafter, clinical correlation has to be studied in a homogeneous group of patients. Immunicon has developed a CellSearch? system to isolate and enumerate circulating tumor cells in an accurate and reproducible manner. CellSearch is an in vitro device capable of reliably isolating and enumerating epithelial cells (CTCs) from human blood samples. The cell analysis is based on optical tracking and detection of immunomagnetically selected and aligned cells 23-24. We now have the opportunity to study the potential role of detecting CTCs in patients with epithelial cancers. With an accurate method to detect and count circulating tumor cells, we propose to correlate CTC numbers before and after primary therapy with outcomes in patients with newly diagnosed breast and colorectal cancers.
|Projectleider||Prof.dr. I.(Istvan) Vermes|
|Instituut||Medlon BV Enschede|
|Periode||1-2001 - 1-2011|
|Partners||Dr. Marco R. de Groot
Dr. Walter JB Mastboom
University of Twente :
Dr. Ir. Arjan GJ Tibbe
|Financiering||1e Geldstroom - Intern